Assisted reproductive technologies in conjunction with conservatively treated endometrial adenocarcinoma. A case report.
This case report illustrates the successful use of assisted reproductive technologies (ARTs) in a patient receiving conservative treatment for endometrial adenocarcinoma. A 31-year-old infertile woman, diagnosed as FIGO stage Ia endometrial adenocarcinoma (grade 1), received oral medroxyprogesterone acetate 400 mg/day for 12 weeks. Endometrial curettage was performed and the absence of endometrial carcinoma was confirmed. A single pregnancy was achieved with in vitro fertilization and embryo transfer. A healthy female infant was born via cesarean section at 42 weeks' gestation. The carcinoma has not recurred, and the patient now desires a second child. We conclude that ART combined with progesterone treatment might be a powerful option for the treatment of infertile patients with early stage, well-differentiated endometrial adenocarcinoma.
Ogawa
S
S
Department of Obstetrics and Gynecology, Jichi Medical School, Minamikawachi-machi, Tochigi 329-0498, Japan.
Koike
T
T
Shibahara
H
H
Ohwada
M
M
Suzuki
M
M
Araki
S
S
Sato
I
I
D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D003475:Curettage; D016889:Endometrial Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D015181:Gamete Intrafallopian Transfer; D006801:Humans; D007247:Infertility, Female / Q000150:complications / Q000628:therapy*; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D011247:Pregnancy; D011256:Pregnancy Outcome
D017258:Medroxyprogesterone Acetate